Pyridopyrimidinone compound and application thereof

By developing pyridopyrimidinone compounds that can effectively inhibit KRAS G12C mutation, we have solved the problem of limited therapeutic effect on cancers related to KRAS G12C mutation in the existing technology, and achieved effective treatment of diseases such as non-small cell lung cancer and colorectal cancer.

CN112159405AActive Publication Date: 2021-01-01GUANGZHOU BEBETTER MEDICINE TECH CO LTD
5 Cites 19 Cited by

Patent Information

Application Number
CN202011182716.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2020-02-04
Filing Date
2020-10-29
Publication Date
2021-01-01
Estimated Expiration
2040-10-29

AI Technical Summary

Technical Problem

Existing treatments for cancers related to KRAS G12C mutations have limited effects and lack effective targeted drugs. Especially in diseases such as non-small cell lung cancer and colorectal cancer, traditional drugs are difficult to effectively inhibit the activity of KRAS protein.

Method used

A new class of pyridopyrimidinone compounds has been developed that can effectively inhibit KRAS G12C mutations and serve as potential therapeutic drugs for the treatment of malignant tumors carrying KRAS G12C mutations, especially non-small cell lung cancer and colorectal cancer.

Benefits of technology

The pyridopyrimidinone compound significantly inhibits KRAS G12C mutation, has strong anti-cell proliferation activity, and has great application value in preventing and treating malignant tumors carrying KRAS G12C mutation.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides a pyridopyrimidinone compound with a structure as shown in a general formula (II) and application thereof. Researches prove that the compound provided by the invention can effectively inhibit KRAS G12C mutation. KRAS mutation accounts for a large proportion in tumors, no approved drug is obtained for treatment at present, and the compound provided by the invention has the potential to become a therapeutic drug for malignant tumors (especially non-small cell lung cancer (NSCLC) and colorectal cancer) carrying KRAS G12C mutation, and has a great application value.
Need to check novelty before this filing date? Find Prior Art